{
  "docId": "019de076-5473-7242-b1c4-ab6acd3f6564",
  "docSlug": "198a0f3704f292567efe1a435af44ee8",
  "documentTitle": "MAIA Biotechnology | Investor Presentation Deck | 39 slides",
  "authorId": "maia-biotechnology",
  "authorName": "MAIA Biotechnology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 39,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide outlines the status of THIO-101, 102, and 103 trials and mentions specific patent filings.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-5473-7242-b1c4-ab6acd3f6564/4",
  "deckHref": "/decks/019de076-5473-7242-b1c4-ab6acd3f6564",
  "deckJsonHref": "/decks/019de076-5473-7242-b1c4-ab6acd3f6564.json",
  "deckAnchorHref": "/decks/019de076-5473-7242-b1c4-ab6acd3f6564#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.09,
        "w": 0.12,
        "x": 0.87,
        "y": 0.02
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "071a036b-592b-4c1b-8511-858e823afe6d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.87,
        "w": 0.32,
        "x": 0.68,
        "y": 0.13
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "497c8171-bf7e-4ed3-9af7-a7945ebb6c23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.65,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "list",
      "text": "Telomere-Targeting Agents: THIO in clinic, Advancing pipeline; Efficacy; Safety; FDA: 2 Orphan Drug Designations (HCC and SCLC); REGN: Clinical Supply Agreement; Phase 2 Go-to-Market Accelerated Approval THIO-101 trial in NSCLC underway (AUS and EU, US IND cleared, Upcoming Milestones: DCR, ORR, Dose Selection, PFS, DoR, OS); Phase 2 Go-to-Market Accelerated Approval THIO-102 basket/umbrella planned to start; Phase 2/3 Confirmatory/Expansion THIO-103 basket trial planned to start; Multiple telomere-targeting compounds designed in-house, 3 filed for patent: MAIA-2021-020, MAIA-2022-012, MAIA-2021-029",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f44f7328-6ea5-4bc6-8c83-47ef043f3425",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "INVESTMENT OVERVIEW",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30449e2e-d03b-4fdb-9892-a121ea606096",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "d125b4bf-62c8-4822-ab56-7ac1d61d1428",
      "evidence": "This presentation highlights basic information about us and the proposed offering.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}